A prospective study for the effect of ferric citrate on FGF23 in patients with normophosphatemic CKD patients with iron deficiency.

A prospective study for the effect of ferric citrate on FGF23 in patients with normophosphatemic CKD patients with iron deficiency. - the effect of ferric citrate on FGF23

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020935

Enrollment

Registered

2016-02-09

Start date

2016-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

ferric citrate hydrate 750mg/day 3months sodium ferrous citrate 50mg/day 3months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) outpatients 2) eGF<45 3) The patients whom Phosphate level is under 4.5 mg/dL 4)iron deficiency (1.ferritin<100pg/ml or 2.100<ferritin<300ng/ml and TSAT<20%) 5) documented informed concent

Exclusion criteria

Exclusion criteria: 1)treatment with phosphate binder or iron supplementation 2) hypersensitivity to lanthanum carbonate and calcium carbonate 3) pregnancy or lactation 4) Any reason for ineligibility suggested by the attending doctor

Design outcomes

Primary

Measure	Time frame
serum FGF23 concentration(after 1 month, 3 months)	—

Countries

Japan

Contacts

Public ContactAkira Iguchi

Saiseikai Niigata Daini Hospital Division of ClinicaNephrology and Rheumatology

igucci4444@yahoo.co.jp025-233-6161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026